Figure 6.
Figure 6. Time course of expression and immune response against hF.IX after systemic administration of hF.IX LVs. The plasma levels of human clotting factor IX were monitored after tail-vein injection of LVs expressing hF.IX from the CMV and ALB promoters and vehicle (PBS) into adult C57BL/6 (A) and BALB/c (B) mice. For the ALB LVs, 2 different amounts of vector were injected: 20 μg (ALB I) and 40 μg (ALB II) p24 vector equivalents. Means + SD, n = 4, are shown. (C-G) ELISA immunoassay was performed on the plasma to detect anti-hF.IX antibodies. Absorbance of the indicated dilutions are shown as mean ± SD, n = 4, for panels C-E, and for individual mice for panels F-G. (H) The vector DNA content was measured in the liver and spleen of C57BL/6 LV-injected mice 25 weeks after injection. Means + SD, n = 3, are shown.

Time course of expression and immune response against hF.IX after systemic administration of hF.IX LVs. The plasma levels of human clotting factor IX were monitored after tail-vein injection of LVs expressing hF.IX from the CMV and ALB promoters and vehicle (PBS) into adult C57BL/6 (A) and BALB/c (B) mice. For the ALB LVs, 2 different amounts of vector were injected: 20 μg (ALB I) and 40 μg (ALB II) p24 vector equivalents. Means + SD, n = 4, are shown. (C-G) ELISA immunoassay was performed on the plasma to detect anti-hF.IX antibodies. Absorbance of the indicated dilutions are shown as mean ± SD, n = 4, for panels C-E, and for individual mice for panels F-G. (H) The vector DNA content was measured in the liver and spleen of C57BL/6 LV-injected mice 25 weeks after injection. Means + SD, n = 3, are shown.

Close Modal

or Create an Account

Close Modal
Close Modal